RNTX Rein Therapeutics, Inc.: institutional ownership and insider trading
66 funds reported holding $43.7M of Rein Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $30.4M, with 19 new positions and 7 funds selling out; over the last 12 months insiders bought $583K and sold $0 on the open market.
Famous investors holding RNTX
- Ken Griffin (Citadel Advisors): $2.54M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $19.8K, 0.0% of the portfolio
Largest institutional holders of RNTX
- Voss Capital, LP — $5.47M
- Cable Car Capital, LP — $5.40M
- ADAR1 Capital Management, LLC — $4.68M
- VANGUARD CAPITAL MANAGEMENT LLC — $3.51M
- BIOS Capital Management, LP — $3.10M
- Ikarian Capital, LLC — $3.07M
- GREAT POINT PARTNERS LLC — $2.68M
- CITADEL ADVISORS LLC — $2.54M
- Velan Capital Investment Management LP — $1.77M
- VANGUARD GROUP INC — $1.35M
Recent RNTX insider trades
- May 27, 2026: Von Rickenbach Josef H bought 47,060 shares ($49.7K)
- Apr 30, 2026: Windsor James Brian bought 25,000 shares ($25.0K)
- Nov 14, 2025: Voss Capital, LP bought 104,183 shares ($127K)
- Oct 28, 2025: Voss Capital, LP bought 306,050 shares ($423K)
5%+ owners
- BIOS CAPITAL MANAGEMENT, LP: 10.0% (Schedule 13G/A, filed May 8, 2026)
- Funicular Funds, LP: 6.7% (Schedule 13G, filed May 7, 2026)
- Voss Capital, LP: 6.6% (Schedule 13G/A, filed Jul 14, 2026)
- ADAR1 Capital Management, LLC: 5.3% (Schedule 13G, filed Aug 14, 2026)
- Lynwood Capital Management Inc.: 5.0% (Schedule 13G/A, filed Aug 14, 2026)